

Pascal Richette

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8201791/publications.pdf>

Version: 2024-02-01

119
papers

5,143
citations

108046

37
h-index

107981

68
g-index

124
all docs

124
docs citations

124
times ranked

6031
citing authors

#	ARTICLE	IF	CITATIONS
1	Metacarpophalangeal Joint Impairment in Hand Osteoarthritis and Its Association With Mechanical Factors: Results From the Digital Cohort Osteoarthritis Design Hand Osteoarthritis Cohort. <i>Arthritis Care and Research</i> , 2022, 74, 1696-1703.	1.5	3
2	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. <i>Arthritis Care and Research</i> , 2022, 74, 1649-1658.	1.5	23
3	How do clinical and socioeconomic factors impact on work disability in early axial spondyloarthritis? Five-year data from the DESIR cohort. <i>Rheumatology</i> , 2022, 61, 2034-2042.	0.9	6
4	Epidemiology of gout and hyperuricemia in New Caledonia. <i>Joint Bone Spine</i> , 2022, 89, 105286.	0.8	8
5	Impact of COVID-19 on initiation of biologic therapy prescriptions for chronic inflammatory diseases. <i>Joint Bone Spine</i> , 2022, 89, 105253.	0.8	1
6	Inhibition of ADAMTS-5: the right target for osteoarthritis?. <i>Osteoarthritis and Cartilage</i> , 2022, 30, 175-177.	0.6	5
7	Fat mass and response to TNF α blockers in early axial spondyloarthritis: an analysis of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 299-300.	0.5	2
8	MRI Features Associated With the Detection of Microbial Pathogens by CT-Guided Biopsy in Septic Spondylodiscitis. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e189-e194.	0.5	0
9	2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis. <i>Joint Bone Spine</i> , 2022, 89, 105344.	0.8	44
10	Actualisation 2022 des recommandations de la Soci�t� fran�aise de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite, incluant le rhumatisme psoriasique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2022, 89, 210-222.	0.0	3
11	Prevalence and consequences of psoriasis in recent axial spondyloarthritis: an analysis of the DESIR cohort over 6 years. <i>RMD Open</i> , 2022, 8, e001986.	1.8	7
12	The shrinking toe sign in gout. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 53, 151981.	1.6	2
13	Do Glucocorticoid Injections Increase the Risk of Knee Osteoarthritis Progression Over 5 Years?. <i>Arthritis and Rheumatology</i> , 2022, 74, 1343-1351.	2.9	14
14	Eosinopenia to differentiate crystal-induced and septic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1201-1202.	0.5	1
15	Patient Perception of Medical Care for Psoriatic Arthritis in North America and Europe: Results from a Global Patient Survey. <i>Rheumatology and Therapy</i> , 2022, 9, 823-838.	1.1	1
16	MRI and ultrasonography for detection of early interphalangeal osteoarthritis. <i>Joint Bone Spine</i> , 2022, 89, 105370.	0.8	4
17	Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. <i>Rheumatology</i> , 2022, 61, 3257-3268.	0.9	11
18	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. <i>RMD Open</i> , 2022, 8, e002031.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Time to Total Knee Arthroplasty after Intra-Articular Hyaluronic Acid or Platelet-Rich Plasma Injections: A Systematic Literature Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3985.	1.0	5
20	Intra-articular injections of platelet-rich plasma in symptomatic knee osteoarthritis: a consensus statement from French-speaking experts. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2021, 29, 3195-3210.	2.3	26
21	Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 349-355.	0.5	52
22	Pain in women with knee and/or hip osteoarthritis is related to systemic inflammation and to adipose tissue dysfunction: Cross-sectional results of the KHOALA cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 129-136.	1.6	16
23	A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. <i>Kidney International</i> , 2021, 99, 218-226.	2.6	45
24	Patient Perceptions of Psoriatic Arthritis Management and Communication with Physicians in Australia: Results from a Patient Survey. <i>Rheumatology and Therapy</i> , 2021, 8, 761-774.	1.1	3
25	A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action. <i>Joint Bone Spine</i> , 2021, 88, 105175.	0.8	14
26	Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1419-1428.	0.5	17
27	Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort. <i>RMD Open</i> , 2021, 7, e001685.	1.8	6
28	The DIGICOD cohort: A hospital-based observational prospective cohort of patients with hand osteoarthritis—methodology and baseline characteristics of the population. <i>Joint Bone Spine</i> , 2021, 88, 105171.	0.8	23
29	Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey. <i>Rheumatology and Therapy</i> , 2021, 8, 1741-1758.	1.1	3
30	Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e482-e490.	0.5	21
31	Uracaemia as a surrogate endpoint in gout trials and the treat-to-target approach for gout management. <i>Lancet Rheumatology</i> , The, 2021, , .	2.2	0
32	Response to “Everything we see is a perspective, not the truth”™ by Chattopadhyay <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e46-e46.	0.5	2
33	2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 31-38.	0.5	225
34	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	1.5	39
35	Iterative percutaneous needle aponeurotomy for Dupuytren's disease: Functional outcome at 5-year follow-up. <i>Joint Bone Spine</i> , 2020, 87, 273-274.	0.8	4
36	Chondrocalcinosis of the Knee and the Risk of Osteoarthritis Progression: Data From the Knee and Hip Osteoarthritis Long-term Assessment Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 726-732.	2.9	17

#	ARTICLE	IF	CITATIONS
37	Can gout management guidelines be solely evidence based?. <i>Nature Reviews Rheumatology</i> , 2020, 16, 479-480.	3.5	2
38	Recommandations de la Société française de rhumatologie pour la prise en charge de la goutte: le traitement hypo-uricémiant. <i>Revue Du Rhumatisme (Edition Française)</i> , 2020, 87, 332-341.	0.0	5
39	Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1 β activation on macrophages. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1506-1514.	0.5	72
40	Traitements symptomatiques et locaux dans le rhumatisme psoriasique. <i>Revue Du Rhumatisme Monographies</i> , 2020, 87, 307-309.	0.0	0
41	High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who's to Blame?. <i>Rheumatology and Therapy</i> , 2020, 7, 1011-1019.	1.1	7
42	Emerging pharmaceutical therapies for osteoarthritis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 673-688.	3.5	211
43	UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis. <i>Joint Bone Spine</i> , 2020, 87, 647-651.	0.8	16
44	FAST: new look at the febuxostat safety profile. <i>Lancet, The</i> , 2020, 396, 1704-1705.	6.3	13
45	Association of Specific Comorbidities with Monosodium Urate Crystal Deposition in Urate-Lowering Therapy-Naive Gout Patients: A Cross-Sectional Dual-Energy Computed Tomography Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1295.	1.0	17
46	Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 701-708.	1.6	11
47	Anti-Saccharomyces cerevisiae IgG and IgA antibodies are associated with systemic inflammation and advanced disease in hidradenitis suppurativa. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 452-455.e5.	1.5	36
48	Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1126-1128.	0.5	11
49	2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares. <i>Joint Bone Spine</i> , 2020, 87, 387-393.	0.8	17
50	2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. <i>Joint Bone Spine</i> , 2020, 87, 395-404.	0.8	47
51	Shoulder adhesive capsulitis: diagnostic value of active and passive range of motion with volume of gleno-humeral capsule as a reference. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2020, 56, 438-443.	1.1	3
52	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019, 71, 427-434.	1.5	73
53	Defining remission in patients with gout. <i>Nature Reviews Rheumatology</i> , 2019, 15, 516-517.	3.5	2
54	Evaluation of the performances of "typical" imaging abnormalities of axial spondyloarthritis: results of the cross-sectional ILOS-DESIR study. <i>RMD Open</i> , 2019, 5, e000918.	1.8	17

#	ARTICLE	IF	CITATIONS
55	Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients. <i>RMD Open</i> , 2019, 5, e000914.	1.8	7
56	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600.	0.5	72
57	Causal Factors for Knee, Hip, and Hand Osteoarthritis: A Mendelian Randomization Study in the UK Biobank. <i>Arthritis and Rheumatology</i> , 2019, 71, 1634-1641.	2.9	109
58	The role of febuxostat in gout. <i>Current Opinion in Rheumatology</i> , 2019, 31, 152-158.	2.0	21
59	Reassessing the Safety Profile of Lesinurad in Combination with Xanthine Oxidase Inhibitor Therapy. <i>Rheumatology and Therapy</i> , 2019, 6, 101-108.	1.1	4
60	SAT0416...ULTRASOUND EVALUATION IN FOLLOW-UP OF URATE-LOWERING THERAPY IN GOUT PHASE 2 (USEFUL-2): DURATION OF FLARE PROPHYLAXIS. , 2019, , .		0
61	SAT0412...DOES THERAPEUTIC EDUCATION IMPROVE GOUT MANAGEMENT: THE EXPERIENCE OF LARIBOISIERE UNIVERSITY HOSPITAL PARIS-FRANCE. , 2019, , .		0
62	OP0052...FAILURE TO REACH SERUM URATE TARGET IS ASSOCIATED WITH ELEVATED MORTALITY IN GOUT. , 2019, , .		0
63	Failure to reach uric acid target of 0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. <i>RMD Open</i> , 2019, 5, e001015.	1.8	49
64	Benefits of Polymerase Chain Reaction Combined With Culture for the Diagnosis of Bone and Joint Infections: A Prospective Test Performance Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz511.	0.4	18
65	Emergence of severe spondyloarthritis-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. <i>Rheumatology</i> , 2019, 58, 963-968.	0.9	42
66	Spinal involvement with calcium pyrophosphate deposition disease in an academic rheumatology center: A series of 37 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1113-1126.	1.6	44
67	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 201-208.	0.5	59
68	Impact du traitement par statines dans la progression radiologique de la gonarthrose: résultats issus de l'analyse post-hoc de l'essai SEKOIA. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019, 86, 81-86.	0.0	0
69	Low incidence of vertebral fractures in early spondyloarthritis: 5-year prospective data of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 60-65.	0.5	9
70	Renal medulla in severe gout: typical findings on ultrasonography and dual-energy CT study in two patients. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 433-434.	0.5	17
71	Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study. <i>Rheumatology</i> , 2019, 58, 410-417.	0.9	30
72	Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. <i>Joint Bone Spine</i> , 2018, 85, 755-760.	0.8	29

#	ARTICLE	IF	CITATIONS
73	Novel uricosurics. <i>Rheumatology</i> , 2018, 57, i42-i46.	0.9	13
74	Investigational drugs for hyperuricemia, an update on recent developments. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 437-444.	1.9	52
75	Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial. <i>Joint Bone Spine</i> , 2018, 85, 609-614.	0.8	29
76	Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy. <i>Arthritis Care and Research</i> , 2018, 70, 918-924.	1.5	12
77	Uric acid and cognitive decline: a double-edge sword?. <i>Current Opinion in Rheumatology</i> , 2018, 30, 183-187.	2.0	37
78	Response to: "Uric acid and incident dementia: a population-based cohort study" by Lee and Song. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e63-e63.	0.5	3
79	International position paper on the appropriate use of uricosurics with the introduction of lesinurad. <i>Clinical Rheumatology</i> , 2018, 37, 3159-3165.	1.0	15
80	Hyperferritinaemia and hyperuricaemia " a causal connection?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 628-629.	3.5	2
81	<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2018, 379, 2209-2219.	13.9	326
82	Accuracy of the HumaSensplus point-of-care uric acid meter using capillary blood obtained by fingertip puncture. <i>Arthritis Research and Therapy</i> , 2018, 20, 78.	1.6	17
83	Colchicine in Gout: An Update. <i>Current Pharmaceutical Design</i> , 2018, 24, 684-689.	0.9	34
84	Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orenca in Rheumatoid Arthritis Registry. <i>Rheumatology</i> , 2017, 56, kew476.	0.9	10
85	Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 748-755.	0.5	251
86	Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. <i>Joint Bone Spine</i> , 2017, 84, 595-598.	0.8	37
87	Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). <i>Nature Reviews Rheumatology</i> , 2017, 13, 561-568.	3.5	74
88	Current and future therapies for gout. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1201-1211.	0.9	39
89	Adherence to Antitumor Necrosis Factor Use Recommendations in Spondyloarthritis: Measurement and Effect in the DESIR Cohort. <i>Journal of Rheumatology</i> , 2017, 44, 1436-1444.	1.0	1
90	Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. <i>BMC Medicine</i> , 2017, 15, 123.	2.3	217

#	ARTICLE	IF	CITATIONS
91	Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates. <i>Cost Effectiveness and Resource Allocation</i> , 2017, 15, 20.	0.6	3
92	Prevalence of Gout in the Adult Population of France. <i>Arthritis Care and Research</i> , 2016, 68, 261-266.	1.5	70
93	Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohort. <i>RMD Open</i> , 2016, 2, e000230.	1.8	14
94	Interaction of HIF1 α and β -catenin inhibits matrix metalloproteinase 13 expression and prevents cartilage damage in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5453-5458.	3.3	94
95	Computational Lexical Analysis of the Language Commonly Used to Describe Gout. <i>Arthritis Care and Research</i> , 2016, 68, 763-768.	1.5	8
96	Weight Loss, Xanthine Oxidase, and Serum Urate Levels: A Prospective Longitudinal Study of Obese Patients. <i>Arthritis Care and Research</i> , 2016, 68, 1036-1042.	1.5	40
97	Measurable definitions of ankylosing spondylitis management recommendations are needed for use in observational studies. <i>Joint Bone Spine</i> , 2016, 83, 101-103.	0.8	5
98	MRI and serum biomarkers correlate with radiographic features in painful hand osteoarthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 991-998.	0.4	13
99	Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort. <i>Joint Bone Spine</i> , 2015, 82, 345-351.	0.8	92
100	Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1725-1733.	0.5	130
101	Revisiting comorbidities in gout: a cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 142-147.	0.5	144
102	Prophylaxis for acute gout flares after initiation of urate-lowering therapy. <i>Rheumatology</i> , 2014, 53, 1920-1926.	0.9	44
103	Treatment of Nongout Joint Deposition Diseases: An Update. <i>Arthritis</i> , 2014, 2014, 1-8.	2.0	11
104	Definition of hyperuricemia and gouty conditions. <i>Current Opinion in Rheumatology</i> , 2014, 26, 186-191.	2.0	336
105	Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. <i>Rheumatology</i> , 2014, 53, 1457-1464.	0.9	25
106	Improving cardiovascular and renal outcomes in gout: what should we target?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 654-661.	3.5	169
107	Biologic agents in osteoarthritis: hopes and disappointments. <i>Nature Reviews Rheumatology</i> , 2013, 9, 400-410.	3.5	186
108	Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. <i>Arthritis Research and Therapy</i> , 2013, 15, R123.	1.6	103

#	ARTICLE	IF	CITATIONS
109	Purine-rich foods: an innocent bystander of gout attacks?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1435-1436.	0.5	18
110	Critical appraisal of the role of pegloticase in the management of gout. <i>Open Access Rheumatology: Research and Reviews</i> , 2012, Volume 4, 63-70.	0.8	8
111	Ultrasonography in gout: a case-control study. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 499-504.	0.4	47
112	The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients. <i>Joint Bone Spine</i> , 2011, 78, 598-603.	0.8	204
113	Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 139-144.	0.5	204
114	An exploratory ultrasound study of early gout. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 816-21.	0.4	39
115	Colchicine for the treatment of gout. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2933-2938.	0.9	37
116	Splint for Base-of-Thumb Osteoarthritis. <i>Annals of Internal Medicine</i> , 2009, 150, 661.	2.0	135
117	Usefulness of taping in lower limb osteoarthritis. French clinical practice guidelines. <i>Joint Bone Spine</i> , 2008, 75, 475-478.	0.8	12
118	Should prednisolone be first-line therapy for acute gout?. <i>Lancet, The</i> , 2008, 372, 1301.	6.3	16
119	Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 338-342.	3.2	36